1 / 33

Initiation of Buprenorphine in the Emergency Department

What is the evidence and how does it work?. Initiation of Buprenorphine in the Emergency Department. Continuing Education Credit: TEXT: 501-406-0076 Activity Code: 31374-24581. Teresa Hudson, PharmD , PhD. Disclosures.

takoda
Download Presentation

Initiation of Buprenorphine in the Emergency Department

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What is the evidence and how does it work? Initiation of Buprenorphine in the Emergency Department Continuing Education Credit: TEXT: 501-406-0076 Activity Code: 31374-24581 Teresa Hudson, PharmD, PhD

  2. Disclosures • Dr. Hudson has a subcontract with the Arkansas Department of Health to provide academic detailing re: buprenorphine in the emergency department. Continuing Education Credit: TEXT: 501-406-0076 Activity Code: 31374-24581

  3. Set Up for Using Poll Everywhere • Text to this number: 22333 • Text this message: Teresahudson735

  4. The Objectives: After completing this one hour presentation the participants will: • Be able to discuss the evidence for the effectiveness of buprenorphine in the ED on treatment engagement for patients with opioid use disorder • Be familiar with assessment tools for establishing opioid use disorder and opioid withdrawal • Understand the process of buprenorphine initiation in the emergency department.

  5. The Evidence • Buprenorphine for treatment of OUD • Reduces mortality • Haley et al JSAT 2019 • Reduces hospital readmission & use of ED • Moreno et al J Addict Med 2019 • Lo-Ciganic et al Addiction 2016

  6. The Evidence Buprenorphine in the ED • One Randomized clinical Trial of Buprenorphine in ED • D’Onofrio et al JAMA 2015 • D’Onofrio et al JGIMS 2017 • Busch et al Addiction 2017 • D’Onofrio et al Imple Science 2019 • One Retrospective chart review of patients who received buprenorphine in the ED- clinical decision unit • Dunkley and colleagues at Grady and Emory Hospitals

  7. The Evidence: One randomized trial – Yale University: • Setting: Large urban teaching hospital • April 2009 – June 2013 • Subjects: included if: • Presented to emergency department for any reason • Screened positive for OUD • UDS positive for opioids • N= 329 • Outcomes • Engagement in treatment at 30 days – based on appts and use of meds • Urine drug screen results • HIV risk behaviors De’Onofrio et al JAMA 2015 and JGIM 2017

  8. The Evidence – D’Onofrio (cont) • Subjects Randomized to: • Referral to treatment (given written card about treatment options) • Brief intervention and facilitated referral • Brief Intervention and Ed-initiated treatment with buprenorphine/naloxone and received appt in primary care within 72 hours • Patients were followed for 10 weeks then transferred to community program or clinician for ongoing treatment • Patients also offered 2-week detox from buprenorphine

  9. The Evidence – D’Onofrio (cont) Intervention Details: • Standard referral to treatment: • Received handout from research assistant • Contained names, locations and telephone numbers of addiction treatment services in the area. • ED allowed them to use the telephone if they wanted to contact treatment during ED visit • Brief Intervention: • 10-15 minute brief negotiation interview • Includes: raising the subject of opioid dependence, provide feedback, enhance motivation and negotiation and advise. • RA discussed treatment options with patients • IF patient wanted treatment, the RA linked the patient with referral including making sure patients was eligible, had insurance and had transportation. • ED Initiated treatment • Received Brief Intervention AND buprenorphine if they exhibited moderate to severe opioid withdrawal. • Received one dose of buprenorphine in the ED with take home doses sufficient to last until primary care appt in 72 hours • Buprenorphine dose: 8mg on day 1, 16mg days 2 and 3. De’Onofrio et al JAMA 2015 and JGIM 2017

  10. The Evidence: (D’Onofrio cont.) De’Onofrio et al JAMA 2015 and JGIM 2017

  11. The Evidence – D’Onofrio (cont) p<0.001 p=0.546 De’Onofrio et al JAMA 2015 and JGIM 2017

  12. The Evidence – D’Onofrio (cont) * *Difference NS

  13. The Evidence – D’Onofrio (cont) * * * * *Difference NS

  14. The Evidence: Cost-Effectiveness? • Cost effectiveness analysis by Yale team: • Costs for personnel time were estimated • ED-initiated buprenorphine : 50 minutes • Referral: 15 minutes • Brief Intervention Referral : 30 minutes • Medication costs: hospital acquisition cost • Cost Perspective: willingness to pay by decision maker

  15. The Evidence: Cost-Effectiveness? • Note: • Costs between the three groups were not significantly different but effectiveness of ED-initiated buprenorphine was more effective in terms of engaging patients in care. • Authors indicated incremental cost effectiveness ratios were calculated but these were not provided in the paper Busch et al Addiction 2017

  16. How it works https://www.drugabuse.gov/nidamed-medical-health-professionals/discipline-specific-resources/initiating-buprenorphine-treatment-in-emergency-department/buprenorphine-integration-pathway https://www.chcf.org/wp-content/uploads/2017/12/PDF-EDMATOpioidProtocols.pdf

  17. Assessment Tools - TAPS • TAPS(https://cde.drugabuse.gov/sites/nida_cde/files/TAPS%20Tool%20Parts%20I%20and%20II%20V2.pdf ) • 2 part screener for substance use • Self administered or interviewer administered • Part 1: tobacco, alcohol, prescription medication and illicit substances in past year. • 5 questions • Part 2: assessment for tobacco, alcohol, illicit substance use and prescription medication misuse for past 3 months • 9 questions McNeeley et al Ann intern med 2016

  18. Assessment Tools DSM-V Diagnosis https://cchealth.org/aod/pdf/DSM-5%20Diagnosis%20Reference%20Guide.pdf

  19. Assessment Tools - COWS • https://www.drugabuse.gov/nidamed-medical-health-professionals/discipline-specific-resources/initiating-buprenorphine-treatment-in-emergency-department/buprenorphine-integration-pathway • Wesson and Ling J Psychoactive Drugs 2003

  20. https://www.drugabuse.gov/nidamed-medical-health-professionals/discipline-specific-resources/initiating-buprenorphine-treatment-in-emergency-department/guide-patients-beginning-buprenorphine-treatment-homehttps://www.drugabuse.gov/nidamed-medical-health-professionals/discipline-specific-resources/initiating-buprenorphine-treatment-in-emergency-department/guide-patients-beginning-buprenorphine-treatment-home

  21. The Process/Logistics • Two Models: • Screen for OUD in ED and initiate buprenorphine in ED if appropriate • Did not appear to cost more in D’Onofrio work • But: D’Onofrio did not specifically examine costs within ED or impact on work flow/wait time • Screen for OUD – if positive transfer to clinical decision unit (CDU) or other short stay unit and initiate buprenorphine • Little Cost data from this scenario

  22. The Process/Barriers and Facilitators to Buprenorphine in the ED • Survey of physicians in two academic medical centers • Web based • Small incentive for response ($10) • Survey domains: • Level of preparation for OUD treatment • Barriers and facilitators to buprenorine in the ED • Demographic information • N=84 (78% response rate) Lowenstein et al Am J Emerg Med 2019 epub

  23. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.) • Respondent Characteristics: • Male: 62% • Race: White • Age: 70% ages 30-49 • X waiver: • N=18/84 (21%) • All were <49 except 1 • Other Characteristics • Attending: 56% • More than 75% time providing clinical care: 73% • Ordered buprenorphine in last 3 months: 33% Lowenstein et al Am J Emerg Med 2019 epub

  24. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.) Lowenstein et al Am J Emerg Med 2019 epub

  25. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.) • Barriers to providing buprenorphine in the ED (top 5) : • Patient Social Barriers • Lack of patient interest • Patient preference for other treatment • Comfort counseling patients receiving buprenorphine* • Comfort ordering buprenorphine* • * - indicates statistically significant different between waivered and non-waivered physicians. This with waivers were more comfortable ordering buprenorphine and counseling patients about buprenorphine Lowenstein et al Am J Emerg Med 2019 epub

  26. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.) • Facilitators to providing buprenorphine in the ED (top 5) • Access to treatment after ED Discharge • Access to dedicated care coordinator/social worker • Order sets for OUD treatment in the EMR • Availability of Pharmacist consultation • Interesting note: Screening for OUD at triage was lowest facilitator and only was with statistically significant difference based on waiver status. This was rated as more important by physicians who were NOT waivered Lowenstein et al Am J Emerg Med 2019 epub

  27. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.) Lowenstein et al Am J Emerg Med 2019 epub

  28. The Process/Barriers and Facilitators to Buprenorphine in the ED (Lowenstein cont.)

  29. Support for Buprenorphine in the ED The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Emergency Medicine (AAEM) and the American College of Emergency Physicians (ACEP), is as follows: ACMT supports the administration of buprenorphine in the emergency department (ED) as a bridge to long-term addiction treatment. Furthermore, ACMT supports the administration of buprenorphine to appropriate patients in the ED to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge. Wax et al J of Med Tech 2019

  30. Continuing Education Credit: TEXT: 501-406-0076 Activity Code: 31374-24581

More Related